Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.56 |
| ▸ | CYP24A1 | Q07973 | 11/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP27B1 | O15528 | 2/20 | 0.51 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983161 | 0.88 | CYP24A1 (0.56) | CYP17A1CYP24A1CYP19A1KDM4ECYP27B1 | |
| SCHEMBL9201425 | 0.86 | CYP19A1 (0.55) | CYP17A1CYP24A1CYP19A1CYP27B1 | |
| SCHEMBL19054890 | 0.85 | CYP17A1 (0.56) | CYP17A1CYP24A1CYP19A1CYP27B1 | |
| SCHEMBL19054884 | 0.85 | MAPT (0.56) | CYP17A1CYP24A1KDM4ECYP27B1 | |
| Hydrochloric Acid SCHEMBL3643107 | 0.85 | CYP17A1 (0.48) | CYP17A1 | |
| SCHEMBL7122603 | 0.82 | CYP17A1 (0.53) | CYP17A1CYP24A1CYP19A1KDM4ECYP27B1 | |
| SCHEMBL9432260 | 0.82 | CYP19A1 (0.58) | CYP17A1CYP19A1KDM4E | |
| Hydrochloric Acid SCHEMBL3650043 | 0.81 | CYP24A1 (0.53) | CYP17A1CYP24A1CYP19A1KDM4E | |
| Hydrochloric Acid SCHEMBL3757776 | 0.80 | CYP19A1 (0.60) | CYP17A1CYP24A1CYP19A1KDM4E | |
| SCHEMBL19054892 | 0.80 | CYP17A1 (0.68) | CYP17A1CYP24A1CYP19A1CYP27B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514145-A1 | IMIDAZOLE COMPOUND, METAL SURFACE TREATMENT LIQUID, METAL SURFACE TREATMENT METHOD, AND LAMINATE PRODUCTION METHOD | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | CYP17A1 556/4885CYP24A1 1700/4885CYP19A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.